Literature DB >> 3060026

Management of congenital adrenal hyperplasia.

I A Hughes1.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3060026      PMCID： PMC1779155          DOI： 10.1136/adc.63.11.1399

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  18 in total

1.  Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia.

Authors:  S Korth-Schutz; R Virdis; P Saenger; D M Chow; L S Levine; M I New
Journal:  J Clin Endocrinol Metab       Date:  1978-03       Impact factor: 5.958

2.  Early diagnosis of salt-losing congenital adrenal hyperplasia in a newborn boy.

Authors:  I A Hughes; J S Winter
Journal:  Can Med Assoc J       Date:  1977-08-20       Impact factor: 8.262

Review 3.  Inborn errors of steroid biosynthesis.

Authors:  M Finkelstein; J M Shaefer
Journal:  Physiol Rev       Date:  1979-04       Impact factor: 37.312

4.  Plasma 17-hydroxyprogesterone concentrations in ill newborn infants.

Authors:  J F Murphy; B G Joyce; J Dyas; I A Hughes
Journal:  Arch Dis Child       Date:  1983-07       Impact factor: 3.791

5.  Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth.

Authors:  M Jansen; J M Wit; J L van den Brande
Journal:  Acta Paediatr Scand       Date:  1981-03

6.  Plasma 17OH-progesterone concentrations in newborn infants.

Authors:  I A Hughes; D Riad-Fahmy; K Griffiths
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

7.  Cortisol production rate. II. Normal infants, children, and adults.

Authors:  F M Kenny; C Preeyasombat; C J Migeon
Journal:  Pediatrics       Date:  1966-01       Impact factor: 7.124

8.  Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia.

Authors:  I A Hughes; G F Read
Journal:  Horm Res       Date:  1982

9.  Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia.

Authors:  I A Hughes; A Wilton; C A Lole; O P Gray
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

10.  Androstenedione rhythms in saliva in congenital adrenal hyperplasia.

Authors:  M C Young; R F Walker; D Riad-Fahmy; I A Hughes
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791
View more
  9 in total

1.  Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency.

Authors:  P E Mullis; P C Hindmarsh; C G Brook
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

2.  Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.

Authors:  I N Silva; C E Kater; C F Cunha; M B Viana
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

3.  The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.

Authors:  M C Young; N Cook; G F Read; I A Hughes
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Monitoring treatment in congenital adrenal hyperplasia.

Authors:  I A Hughes
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

5.  Response to treatment of congenital adrenal hyperplasia in infancy.

Authors:  M C Young; I A Hughes
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

6.  Growth and body proportions in congenital adrenal hyperplasia.

Authors:  M C Young; J Ribeiro; I A Hughes
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

7.  Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia.

Authors:  Kyriakie Sarafoglou; John H Himes; Jean M Lacey; Brian C Netzel; Ravinder J Singh; Dietrich Matern
Journal:  Horm Res Paediatr       Date:  2010-08-25       Impact factor: 2.852

8.  Dexamethasone treatment for congenital adrenal hyperplasia.

Authors:  M C Young; I A Hughes
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

9.  Management of 21-hydroxylase deficiency congenital adrenal hyperplasia: A survey of Canadian paediatric endocrinologists.

Authors:  Robert Stein; Diane Wherrett; Denis Daneman
Journal:  Paediatr Child Health       Date:  2005-07       Impact factor: 2.253
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.